John Murphy serves as the Chief Policy Officer at the Biotechnology Innovation Organization (BIO). BIO is the largest trade association in the world representing biotechnology companies. BIO members are involved in the research and development of innovative healthcare, agricultural, and environmental biotechnology products, thereby expanding the boundaries of science to benefit humanity by providing better healthcare, enhanced agriculture, and a cleaner and safer environment.
Mr. Murphy leads the policy functions, both domestic and international, for all healthcare, agricultural, and environmental biotechnology advocacy across the Organization. BIO’s policy and advocacy centers on developing and implementing legislative and international policies that foster a robust ecosystem for novel biotechnology development throughout the world. Biotech innovation focuses on the development of first-in-kind medicines to treat unmet medical needs, climate technologies to address global climate change issues, and groundbreaking agricultural developments that seek to strengthen and expand the global food supply.
Additionally, Mr. Murphy directs the legal functions of the Organization’s healthcare division. This role encompasses all legal issues impacting healthcare biotechnology across the country, with responsibilities including oversight of Congressional legislation, FDA, CMS and various other federal agency regulatory issues, litigation, and support on state-developed biotechnology laws and regulations. Mr. Murphy is a frequent speaker on issues associated with patient access to prescription medicines, prescription drug abuse, drug pricing, and more general issues impacting medicine approvals and innovation in the United States.
Mr. Murphy is a graduate of Villanova University and the Catholic University Columbus School of Law. Previously, he worked on healthcare regulatory and enforcement issues at Hogan Lovells, LLP, and served as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Mr. Murphy leads the policy functions, both domestic and international, for all healthcare, agricultural, and environmental biotechnology advocacy across the Organization. BIO’s policy and advocacy centers on developing and implementing legislative and international policies that foster a robust ecosystem for novel biotechnology development throughout the world. Biotech innovation focuses on the development of first-in-kind medicines to treat unmet medical needs, climate technologies to address global climate change issues, and groundbreaking agricultural developments that seek to strengthen and expand the global food supply.
Additionally, Mr. Murphy directs the legal functions of the Organization’s healthcare division. This role encompasses all legal issues impacting healthcare biotechnology across the country, with responsibilities including oversight of Congressional legislation, FDA, CMS and various other federal agency regulatory issues, litigation, and support on state-developed biotechnology laws and regulations. Mr. Murphy is a frequent speaker on issues associated with patient access to prescription medicines, prescription drug abuse, drug pricing, and more general issues impacting medicine approvals and innovation in the United States.
Mr. Murphy is a graduate of Villanova University and the Catholic University Columbus School of Law. Previously, he worked on healthcare regulatory and enforcement issues at Hogan Lovells, LLP, and served as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).
Speaking In
11:00 AM - 12:00 PM
Tuesday, June 6
3:00 PM - 4:00 PM
Wednesday, June 7
4:15 PM - 5:15 PM
Wednesday, June 7
9:00 AM - 10:00 AM
Thursday, June 8
